临床试验/NCT06868849

NCT06868849招募中1 期

A Phase Ia/II, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT203 in Patients With Cancer Cachexia

Shanghai JMT-Bio Inc.1 个研究点分布在 1 个国家目标入组 307 人开始时间: 2024年5月15日最近更新: 2026年5月22日

适应症

试验速览

阶段: 1 期
状态: 招募中
发起方
入组人数: 307
试验地点: 1
主要终点: Phase Ia: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

A Phase Ia/II, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT203 in Patients with Cancer Cachexia

详细描述

This is a study of JMT203 in patients with cancer cachexia, comprising two parts: Phase Ia, which involves a dose-escalation and dose-expansion study of JMT203 in patients with cancer cachexia, and Phase II, which is a multicenter, randomized, double-blind, placebo-controlled clinical study. The phase II stage includes three cohorts: Cohort A (participants with colorectal cancer cachexia), Cohort B (participants with pancreatic cancer cachexia), and Cohort C (participants with cachexia from other solid tumors) . The primary objectives of Phase Ia are to assess the safety/tolerability of JMT203 in patients with cancer cachexia and to determine the maximum tolerated dose (MTD) (if any) and/or the recommended dose for expansion (RDE) of JMT203. In Phase II, the primary objectives include evaluating the preliminary efficacy of JMT203 at doses of 50 mg and 150 mg versus placebo over a 12-week treatment period and determining the recommended Phase 3 dose (RP3D) of JMT203.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Single (Participant)

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Inclusion Criteria:
•Age ≥ 18 years old;
•Voluntarily participate in the study and sign the informed consent form;
•Inclusion Criteria:
•Age ≥ 18 years old;
•Voluntarily participate in the study and sign the informed consent form;
•Malignant solid tumors confirmed histologically or cytologically, with ongoing or completed anti-tumor treatment, and no significant tumor progression within 28 days prior to the first drug administration，and the investigator estimates that the participant will not require a switch to another anticancer therapy due to disease progression during the first treatment cycle (21 days). For the Phase II portion:
•Cohort A (participants with colorectal cancer cachexia): Must meet the following treatment status: currently receiving or about to initiate investigator-selected second-line standard anticancer therapy, with no more than 5 cycles of second-line therapy, and not suitable for immune checkpoint inhibitors.;
•Cohort B (participants with pancreatic cancer cachexia): Must meet the following treatment status: currently receiving or about to initiate investigator-selected first-line standard anticancer therapy, with no more than 3 cycles of first-line therapy, and not suitable for targeted therapy.;
•Cohort C (participants with cachexia from other solid tumors): Currently receiving or have completed investigator-selected standard anticancer therapy, with no more than three prior lines of therapy.
•Diagnosed with cancer cachexia according to the criteria of the 2011 International Consensus on Cancer Cachexia: Definition and Classification, combined with characteristics of the Chinese population, i.e., presenting with one of the following within 6 months (previous weight data must be supported by written documentation approved by the sponsor): involuntary weight loss >5%, or weight loss >2% when Body Mass Index （BMI） <18.5 kg/m²;
•Adequate organ function, meeting relevant laboratory test standards （without transfusion or hematopoietic growth factor support within 14 days prior to testing）:
•Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: ≤1;
•7. Eastern Cooperative Oncology Group Performance Status （ECOG PS）score: ≤2;
•Estimated survival ≥4 months;
•Fertile eligible patients must use adequate contraceptive measures from the time of signing the informed consent form until 6 months after the last drug administration; female patients of childbearing age must have a negative serum pregnancy test within 7 days before the first drug administration.

排除标准

•Presence of reversible causes leading to decreased food intake;
•Patients with dysphagia or poor food digestion and absorption, including gastrointestinal obstruction, active inflammatory bowel disease, or short bowel syndrome;
•Patients with cachexia caused by clearly identified other causes, such as severe chronic obstructive pulmonary disease, uncontrolled thyroid disease, vital organ failure, or Acquired Immune Deficiency Syndrome （AIDS）;
•Patients receiving tube feeding or parenteral nutrition therapy during the screening period;
•Patients who have taken any prescription medications for appetite enhancement or improve weight loss within 28 days or 5 half-lives (whichever is shorter) before the first study drug administration, including but not limited to anamorelin, medroxyprogesterone acetate, dronabinol, medical marijuana, etc.;
•Initiation of systemic glucocorticoids (prednisone >10 mg/day or equivalent doses of other similar drugs) or other immunosuppressive therapies within 28 days before the first study drug administration, excluding pretreatment for antitumor therapy;
•Patients with a BMI exceeding 30 kg/m²;
•Patients who have undergone major surgery within 4 weeks before the first study drug administration and have not recovered, or are expected to undergo major surgery during the study;
•Patients who have received other clinical study medications within 4 weeks or 5 half-lives (whichever is shorter) before the first study drug administration;
•Patients with severe infections requiring intravenous antibiotics, antivirals, or antifungals during the screening period;
•Patients with difficult-to-control moderate to large amounts of serous cavity effusion, such as pericardial effusion or pleural/abdominal/pelvic effusion, within 14 days before the first study drug administration;
•Patients with a second primary active malignancy within 2 years before the first study drug administration, excluding locally curable tumors that have undergone radical treatment (e.g., resected basal cell or squamous cell skin cancer, superficial bladder cancer, breast carcinoma in situ);
•Patients with active central nervous system metastases (brain metastases, carcinomatous meningitis, and spinal cord metastases), except for those with controlled lesions confirmed by imaging studies within 28 days before the first use of the investigational product;
•History of severe cardiovascular disease, including but not limited to:
•Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, second- or third-degree atrioventricular block, etc.;
•Occurrence of acute coronary syndrome, congestive heart failure, stroke, or other cardiovascular events of grade 3 or higher within 6 months before the first study drug administration;
•New York Heart Association functional class ≥III or left ventricular ejection fraction (LVEF) <50%;
•Patients with severe immune deficiency or a history of organ transplantation;
•Patients with recent (within the past year) or current depression or suicidal ideation/tendencies;
•Known allergy to JMT203 or its components;
•History of severe allergic reactions or uncontrollable allergic asthma;
•Patients deemed unsuitable for participation in this clinical study by the investigator for other reasons.

结局指标

主要结局

Phase Ia: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).

时间窗: Up to 90 days after the last dose of JMT203

Phase Ia: Incidence of dose-limiting toxicity (DLT) events

时间窗: Up to 21 days after the first dose of JMT203

Phase Ia: MTD (if applicable).

时间窗: Up to 90 days post last dose

Phase Ia: RDE.

时间窗: Up to 90 days post last dose

Phase Ib: Average change in body weight from baseline at each assessment timepoint within 12 weeks.

时间窗: Within 12 weeks from baseline

次要结局

Phase Ia: Area under the curve from time "0" to the time of the last measurable concentration (AUC0-t) of JMT203(Up to 90 days after the last dose of JMT203)
Phase Ia: Maximum measured plasma concentration (Cmax) of JMT203(Up to 90 days after the last dose of JMT203)
Phase Ia: Time when Cmax occurred (Tmax) of JMT203(Up to 90 days after the last dose of JMT203)
Phase Ia: The PD indicators include β-hydroxybutyric acid.(Up to 12 weeks)
Phase Ia: Incidence of anti-drug antibodies (ADA).(Up to 90 days after the last dose of JMT203)
Phase Ia: Average change in body weight from baseline at each assessment timepoint within 12 weeks(Within 12 weeks from baseline)
Phase Ib: Average change in the skeletal muscle index (SMI) of the third lumbar vertebra, measured by computed tomography (CT), from baseline to 12 weeks.(Within 12 weeks from baseline)
Phase Ib: Average change in the severity of anorexia (based on the Functional Assessment of Anorexia/Cachexia Therapy - Anorexia/Cachexia Subscale [FAACT-A/CS]) from baseline to each assessment timepoint.(Within 12 weeks from baselineUp until the end of the treatment)
Phase Ib: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).(Up to 90 days after the last dose of JMT203)
Phase Ib: Blood concentration of JMT203;(Up to 90 days after the last dose of JMT203)
Phase Ib: PD indicators include β-hydroxybutyric acid.(Up to 24 weeks)
Phase Ib: Incidence of ADA.(Up to 90 days after the last dose of JMT203)
Phase Ib: overall survival (OS).(Approximately up to 3 years)

研究者

发起方

Shanghai JMT-Bio Inc.

申办方类型

Industry

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

进行中（未招募）

1 期

A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid TumorsAdvanced Solid Tumors

NCT05114759Suzhou Suncadia Biopharmaceuticals Co., Ltd.176

已完成

1 期

Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain TumourRecurrent GlioblastomaBrain Tumor

NCT00503204AstraZeneca20

已完成

1 期

Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid TumorsHigh-grade Serous Ovarian CancerSolid TumorsNUT Midline CarcinomaTriple-Negative Breast Cancer

NCT02307240Curis, Inc.43

招募中

1 期

ZZ06 in Adult Patients With Advanced Solid Tumor MalignanciesAdvanced EGFR Positive Solid Tumor

NCT04412616Changchun Intellicrown Pharmaceutical Co. LTD60

已完成

1 期

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate CancerProstate Cancer

NCT04087174AstraZeneca27